Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Short communication: T cell activation in HIV-1/herpes simplex virus-2-coinfected Kenyan women receiving valacyclovir.

Roxby AC, Liu AY, Drake AL, Kiarie JN, Richardson B, Lohman-Payne BL, John-Stewart GC, Wald A, De Rosa S, Farquhar C.

AIDS Res Hum Retroviruses. 2013 Jan;29(1):94-8. doi: 10.1089/AID.2012.0071. Epub 2012 Sep 4.

2.

A randomized controlled pilot trial of valacyclovir for attenuating inflammation and immune activation in HIV/herpes simplex virus 2-coinfected adults on suppressive antiretroviral therapy.

Yi TJ, Walmsley S, Szadkowski L, Raboud J, Rajwans N, Shannon B, Kumar S, Kain KC, Kaul R, Tan DH.

Clin Infect Dis. 2013 Nov;57(9):1331-8. doi: 10.1093/cid/cit539. Epub 2013 Aug 14.

PMID:
23946220
3.

Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial.

Zuckerman RA, Lucchetti A, Whittington WL, Sanchez J, Coombs RW, Zuñiga R, Magaret AS, Wald A, Corey L, Celum C.

J Infect Dis. 2007 Nov 15;196(10):1500-8. Epub 2007 Oct 31.

PMID:
18008230
4.

The effect of valacyclovir on HIV and HSV-2 in HIV-infected persons on antiretroviral therapy with previously unrecognised HSV-2.

Van Wagoner N, Geisler WM, Bachmann LH, Hook EW.

Int J STD AIDS. 2015 Jul;26(8):574-81. doi: 10.1177/0956462414546504. Epub 2014 Aug 21.

PMID:
25147236
5.

Effects of valacyclovir on markers of disease progression in postpartum women co-infected with HIV-1 and herpes simplex virus-2.

Roxby AC, Drake AL, Ongecha-Owuor F, Kiarie JN, Richardson B, Matemo DN, Overbaugh J, Emery S, John-Stewart GC, Wald A, Farquhar C.

PLoS One. 2012;7(6):e38622. doi: 10.1371/journal.pone.0038622. Epub 2012 Jun 12.

6.

High-dose valacyclovir decreases plasma HIV-1 RNA more than standard-dose acyclovir in persons coinfected with HIV-1 and HSV-2: a randomized crossover trial.

Perti T, Saracino M, Baeten JM, Johnston C, Diem K, Ocbamichael N, Huang ML, Selke S, Magaret A, Corey L, Wald A.

J Acquir Immune Defic Syndr. 2013 Jun 1;63(2):201-8. doi: 10.1097/QAI.0b013e3182928eea.

7.

High-dose valacyclovir HSV-2 suppression results in greater reduction in plasma HIV-1 levels compared with standard dose acyclovir among HIV-1/HSV-2 coinfected persons: a randomized, crossover trial.

Mugwanya K, Baeten JM, Mugo NR, Irungu E, Ngure K, Celum C.

J Infect Dis. 2011 Dec 15;204(12):1912-7. doi: 10.1093/infdis/jir649. Epub 2011 Oct 12.

8.

Herpes Simplex Virus Suppressive Therapy in Herpes Simplex Virus-2/Human Immunodeficiency Virus-1 Coinfected Women Is Associated With Reduced Systemic CXCL10 But Not Genital Cytokines.

Andersen-Nissen E, Chang JT, Thomas KK, Adams D, Celum C, Sanchez J, Coombs RW, McElrath MJ, Baeten JM.

Sex Transm Dis. 2016 Dec;43(12):761-764.

9.

Valacyclovir for herpes simplex virus infection: long-term safety and sustained efficacy after 20 years' experience with acyclovir.

Tyring SK, Baker D, Snowden W.

J Infect Dis. 2002 Oct 15;186 Suppl 1:S40-6. Review.

PMID:
12353186
10.

Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 coinfected women: a randomized, placebo-controlled, cross-over trial.

Baeten JM, Strick LB, Lucchetti A, Whittington WL, Sanchez J, Coombs RW, Magaret A, Wald A, Corey L, Celum C.

J Infect Dis. 2008 Dec 15;198(12):1804-8. doi: 10.1086/593214.

11.

Valacyclovir suppressive therapy reduces plasma and breast milk HIV-1 RNA levels during pregnancy and postpartum: a randomized trial.

Drake AL, Roxby AC, Ongecha-Owuor F, Kiarie J, John-Stewart G, Wald A, Richardson BA, Hitti J, Overbaugh J, Emery S, Farquhar C.

J Infect Dis. 2012 Feb 1;205(3):366-75. doi: 10.1093/infdis/jir766. Epub 2011 Dec 6.

12.

A missed point in deciphering the viral synergy between herpes simplex virus and HIV.

Lisco A, Vanpouille C, Margolis L.

Lancet Infect Dis. 2009 Sep;9(9):522-3. doi: 10.1016/S1473-3099(09)70209-9. No abstract available.

13.

A pilot study examining the safety and tolerability of valacyclovir in veterans with hepatitis C virus/herpes simplex virus type 2 coinfection.

Burton MJ, Penman A, Sunesara I, McGuire BM, Hook EW 3rd.

Am J Med Sci. 2014 Dec;348(6):455-9. doi: 10.1097/MAJ.0000000000000321.

PMID:
25163019
14.

Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus.

Nagot N, Ouédraogo A, Foulongne V, Konaté I, Weiss HA, Vergne L, Defer MC, Djagbaré D, Sanon A, Andonaba JB, Becquart P, Segondy M, Vallo R, Sawadogo A, Van de Perre P, Mayaud P; ANRS 1285 Study Group.

N Engl J Med. 2007 Feb 22;356(8):790-9.

15.

Impact of suppressive herpes therapy on genital HIV-1 RNA among women taking antiretroviral therapy: a randomized controlled trial.

Ouedraogo A, Nagot N, Vergne L, Konate I, Weiss HA, Defer MC, Foulongne V, Sanon A, Andonaba JB, Segondy M, Mayaud P, Van de Perre P.

AIDS. 2006 Nov 28;20(18):2305-13.

PMID:
17117016
16.
17.

Valacyclovir prophylaxis to prevent recurrent herpes at delivery: a randomized clinical trial.

Sheffield JS, Hill JB, Hollier LM, Laibl VR, Roberts SW, Sanchez PJ, Wendel GD Jr.

Obstet Gynecol. 2006 Jul;108(1):141-7. Erratum in: Obstet Gynecol. 2006 Sep;108(3 Pt 1):695.

PMID:
16816068
18.

Valacyclovir therapy does not reverse herpes-associated alterations in cervical immunology: a randomized, placebo-controlled crossover trial.

Yi TJ, Shannon B, Chieza L, Su D, Saunders M, Tharao W, Huibner S, Remis R, Raboud J, Kaul R.

J Infect Dis. 2014 Sep 1;210(5):708-12. doi: 10.1093/infdis/jiu163. Epub 2014 Mar 23.

PMID:
24664172
19.

HSV suppression reduces seminal HIV-1 levels in HIV-1/HSV-2 co-infected men who have sex with men.

Zuckerman RA, Lucchetti A, Whittington WL, Sánchez J, Coombs RW, Magaret A, Wald A, Corey L, Celum C.

AIDS. 2009 Feb 20;23(4):479-83. doi: 10.1097/QAD.0b013e328326ca62.

20.

Supplemental Content

Support Center